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The approach of severe sepsis and septic shock has three
fundamental steps: early recognition, hemodynamic
resuscitation and early empiric antibiotic therapy with
focus control if appropriate. Empiric antibiotic therapy
involves two decisions: the choice of antibiotics, which
depends on the presumed focus and pathogens, and dosing
of antibiotics, which should be appropriate along with a
correct route and mode of administration [1].
In a recent issue of Intensive Care Medicine, Jan De
Waele et al. [2] presented data from the Defining Antibiotic
Levels in Intensive care unit patients (DALI) study look-
ing at patient characteristics predictive of non-attainment
of pharmacokinetic/pharmacodynamic (PK/PD) targets,
namely f T [ MIC of the suspected pathogen for at least 50
and 100 % of the dosing interval, in intensive care unit (ICU)
patients receiving eight different b-lactams. The DALI
project [3] is an international prospective, multicentre,
pharmacokinetic point prevalence study involving 68 hos-
pitals, ten countries, with a total of 343 patients, of whom 259
had infection. In the present study, 57 % of patients received
penicillins, 27 % carbapenems, and 16 % cephalosporins.
Dosing was at the discretion of the treating clinician.
In the present study, antibiotics were given for treat-
ment of infection in 75.5 % of patients; however, there
was no information on the rate of microbiological docu-
mentation or on the bacterial antibiotic susceptibility. The
aim of the study was to evaluate target non-attainment
neither for the actual infection nor for the microbiological
agents, but envisioning an empirical situation where the
least susceptible organism was potentially causing the
infection. To overcome this weakness, recognized by the
authors, they assume that the concentrations obtained in
the DALI study were also the concentrations that would
be reached during empirical dosing. Accordingly, the
authors calculate the non-attainment of PK/PD targets
using the highest European Committee on Antimicrobial
Susceptibility Testing (EUCAST) MIC90 data breakpoint
for the administered antibiotic among all potential
pathogens. The rationale for this choice was that empiric
antibiotic dose selection is based on the ‘worst-case’
scenario in terms of bacterial susceptibility.
The authors showed that free antibiotic concentrations
remained below the least susceptible MIC during 50 and
100 % of the dosing interval in 66 (19.2 %) and 142
(41.4 %) patients, respectively. By multivariate analysis,
they found that intermittent infusion (vs. extended or
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continuous infusion) was significantly associated with
target non-attainment (either 50 or 100 % f T [ MIC),
and that high creatinine clearance (CLCR), measured with
the Cockcroft–Gault formula, was only associated with
100 % f T [ MIC non-attainment.
The use of the Cockcroft–Gault formula to estimate
CLCR raises several concerns since it has been repeatedly
shown to be inaccurate in the critical care setting, in
particular in patients showing augmented renal clearance
[4]. Only measured CLCR should be used to accurately
guide drug dosing [5].
The authors also showed that, in patients treated with
intermittent infusion, antibiotics for prophylaxis was the
only identified risk factor for not achieving a 50 %
f T [ MIC. This finding is difficult to explain since we
could assume that patients under antibiotic prophylaxis
were less severely ill, since at least some could have been
subjected to elective surgery, and as a result should have
normal or near normal volume of distribution (Vd); how-
ever, on the other hand, they could present high CLCR that
could be the reason for target PK/PD non-attainment since
surgery has been repeatedly shown to be a risk factor for
augmented renal clearance. Concerning the target 100 %
f T [ MIC, the identified risk factors of non-attainment
were high CLCR, recent surgery and the first days of ther-
apy. All these factors are expected to influence PK as they
markedly influence antibiotic clearance and Vd [6].
Target non-attainment was also assessed in a sub-
analysis looking into the three most frequently adminis-
tered antibiotics, i.e. piperacillin, meropenem and
amoxicillin. Interestingly, the risk of target non-attain-
ment was very high with amoxicillin used in conventional
doses; almost 90 % of patients did not attain the 100 %
f T [ MIC. However, more worrisome was that in more
than 50 % of patients treated with conventional doses of
amoxicillin, 50 % f T [ MIC was not attained! This is in
contrast to meropenem; when used in conventional doses
and regardless of the method of administration, almost all
patients reach 50 % f T [ MIC of the dosing interval and
less than 30 % did not attain 100 % f T [ MIC. These
findings, not discussed by the authors, should be carefully
scrutinized in the light of the accepted PK/PD targets for
the treatment of bacterial infections for cephalosporins
and penicillins f T [ MIC C 50 % and for carbapenems
f T [ MIC C 40 % [7]. Consequently, the data from the
present study points to the fact that, at least for merope-
nem, the proposed conventional dose attains the PK/PD
target in almost all patients irrespective of the mode of
administration, raising questions when looking into the
contrasting results of the recently published randomised
controlled trials [8, 9]. On the other hand, the very high
frequency of non-attainment of PK/PD target with
amoxicillin raises the issue of underdosing encountered
with the widely used conventional dosing.
Besides underdosing, the issues of antibiotic accumula-
tion and neurologic toxicity of b-lactams, not been evaluated
in this study, have been well documented [10, 11] in par-
ticular in patients with renal and/or hepatic dysfunction.
One of the main messages of the present study is that
with extended or continuous infusion of b-lactams the risk
of non-attainment of target PK/PD decreases markedly. In
spite of the well-known PK benefits of this strategy,
studies have repeatedly failed to show a significant impact
on mortality [12, 13]. As a result further clinical studies
are needed to assess the impact of this strategy, continu-
ous infusion of b-lactams, on patient outcomes.
Therapeutic drug monitoring (TDM) would help clini-
cians in the safe adjustment of the dose, especially when
cheap, reliable and timely documentation of antibiotic
concentrations becomes widely available. However, we are
not there yet as PK/PD targets (especially in ICU patients),
the effect of TDM on clinical cure and ICU mortality, are
still all matter of debate. Meanwhile, studies elucidating
antibiotic underdosing in ICU patients, such as the one
conducted by De Waele et al., are warmly welcomed.
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